Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.

ABSTRACT:

Background

Randomized, controlled trials comparing long-acting muscarinic antagonist (LAMA) efficacy in COPD are limited. This network meta-analysis (NMA) assessed the relative efficacy of tiotropium 18 µg once-daily (OD) and newer agents (aclidinium 400 µg twice-daily, glycopyrronium 50 µg OD, and umeclidinium 62.5 µg OD).

Methods

A systematic literature review identified randomized, controlled trials of adult COPD patients receiving LAMAs. A NMA within a Bayesian framework examined change from baseline in trough forced expiratory volume in 1 second (FEV1), transitional dyspnea index focal score, St George's Respiratory Questionnaire score, and rescue medication use.

Results

Twenty-four studies (n=21,311) compared LAMAs with placebo/each other. Aclidinium, glycopyrro

SUBMITTER: Ismaila AS 

PROVIDER: S-EPMC4655912 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature